What question did this study set out to answer?

Repurposing PARP Inhibitors in Peritoneal Metastatic Colorectal Cancer Models

View Full Paper

Ask AI

Bookmark

This research aims to explore the effectiveness of PARP inhibitors in peritoneal metastatic colorectal cancer (pmCRC) identified through molecular profiling.
Established 48 patient-derived xenograft (PDX) models from pmCRC patients.
Classified 14 PDX as homologous recombination deficient (HRD) and 34 as proficient using RNA sequencing.
Analyzed treatment responses to 5-Fluorouracil (5-FU) and olaparib in predicted resistant pmCRC models.
Identified specific genomic alterations linked to 5-FU resistance in pmCRC.
12 HRD pmCRC models showed sensitivity to PARP inhibitors despite being resistant to 5-FU.
Response data demonstrated the promise of molecular profiling for personalized treatment strategies.

No takes yet. Share an insight, caveat, or question.

Preclinical analysis shows potential of PARP inhibitors in treating resistant peritoneal metastatic colorectal cancer.

Dahlmann et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark